Supplemental dose of antithrombin use in disseminated intravascular coagulation patients after abdominal sepsis

Thrombosis and Haemostasis

Volumn 114, Issue 3, 2015, Pages 537-545

  Tagami, Takashi ^a,b   Matsui, Hiroki ^a   Fushimi, Kiyohide ^c   Yasunaga, Hideo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Antithrombin; Disseminated intravascular coagulation; Sepsis; Surgery

Indexed keywords

ANTITHROMBIN;

ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; CARDIOVASCULAR MORTALITY; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; FEMALE; HUMAN; LAPAROTOMY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; SEPSIS; VERY ELDERLY; ADOLESCENT; BLOOD; CHI SQUARE DISTRIBUTION; COMPLICATION; DISSEMINATED INTRAVASCULAR COAGULATION; FACTUAL DATABASE; INTESTINAL PERFORATION; MICROBIOLOGY; ODDS RATIO; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; SHOCK, SEPTIC; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTITHROMBINS; CHI-SQUARE DISTRIBUTION; DATABASES, FACTUAL; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; HUMANS; INTESTINAL PERFORATION; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; RESPIRATION, ARTIFICIAL; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SHOCK, SEPTIC; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84940667911     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH15-01-0053     Document Type: Article

References (48)

1. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med 2013; 369: 840–851
2. Gando S, Iba T, Eguchi Y, et al. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med 2006; 34: 625–631
3. Gando S, Saitoh D, Ogura H, et al. Natural history of disseminated intravascular coagulation diagnosed based on the newly established diagnostic criteria for critically ill patients: results of a multicenter, prospective survey. Crit Care Med 2008; 36: 145–150
4. Hunt BJ. Bleeding and coagulopathies in critical care. N Engl J Med 2014; 370: 847–859
5. Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999; 341: 586–592
6. Dhainaut JF, Shorr AF, Macias WL, et al. Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failure. Crit Care Med 2005; 33: 341–348
7. Fourrier F. Severe sepsis, coagulation, and fibrinolysis: dead end or one way? Crit Care Med 2012; 40: 2704–2708
8. Wiedermann CJ. Clinical review: molecular mechanisms underlying the role of antithrombin in sepsis. Crit Care 2006; 10: 209
9. Iba T, Gando S, Thachil J. Anticoagulant therapy for sepsis-associated disseminated intravascular coagulation: the view from Japan. J Thromb Haemost 2014; 12: 1010–1019
10. Fourrier F, Chopin C, Huart JJ, et al. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 1993; 104: 882–888
11. Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. J Am Med Assoc 2001; 286: 1869–1878
12. Afshari A, Wetterslev J, Brok J, et al. Antithrombin III in critically ill patients: systematic review with meta-analysis and trial sequential analysis. Br Med J 2007; 335: 1248–1251
13. Eid A, Wiedermann CJ, Kinasewitz GT. Early administration of high-dose antithrombin in severe sepsis: single center results from the KyberSept-trial. Anesth Analg 2008; 107: 1633–1638
14. Rublee D, Opal SM, Schramm W, et al. Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Crit Care 2002; 6: 349–356
15. Wiedermann CJ, Hoffmann JN, Juers M, et al. High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Crit Care Med 2006; 34: 285–292
16. Wiedermann CJ, Kaneider NC. A systematic review of antithrombin concentrate use in patients with disseminated intravascular coagulation of severe sepsis. Blood Coagul Fibrinolysis 2006; 17: 521–526
17. Oda S, Aibiki M, Ikeda T, et al. The Japanese Guidelines for the Management of Sepsis. J Intensive Care 2014; 2: 55
18. Iba T, Saito D, Wada H, et al. Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: A prospective multicenter survey. Thromb Res 2012; 130: e129-e133
19. Iba T, Saitoh D, Wada H, et al. Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: a secondary survey. Crit Care 2014; 18: 497
20. Gando S, Saitoh D, Ishikura H, et al. A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Crit Care 2013; 17: R297
21. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303–1310
22. Tagami T, Matsui H, Horiguchi H, et al. Antithrombin and mortality in severe pneumonia patients with sepsis-associated disseminated intravascular coagulation: an observational nationwide study. J Thromb Haemost 2014; 12: 1470–1479
23. Tagami T, Matsui H, Horiguchi H, et al. Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients. Eur Respir J 2015; 45: 463–472
24. Tagami T, Matsui H, Horiguchi H, et al. Recombinant human soluble thrombomodulinand mortality in severe pneumonia patients with sepsis-associated disseminated intravascular coagulation: an observational nationwide study. J Thromb Haemost 2015; 13: 31–40
25. Schoenfeld DA, Bernard GR. Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome. Crit Care Med 2002; 30: 1772–1777
26. Austin PC. The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med 2014; 33: 1242–1258
27. Rosenbaum P, Rubin D. Constructing a control-group using multivariate matched sampling methods that incorporate the propensity score. Am Stat 1985; 39: 33–38
28. Curtis LH, Hammill BG, Eisenstein EL, et al. Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases. Med Care 2007; 45: S103–107
29. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41: 580–637
30. de Stoppelaar SF, van ’t Veer C, van der Poll T. The role of platelets in sepsis. Thromb Haemost 2014; 112: 666–677
31. Austin PC. Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research. Communications in Statistics – Simulation and Computation 2009; 38: 1228–1234
32. Stukel TA, Fisher ES, Wennberg DE, et al. Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. J Am Med Assoc 2007; 297: 278–285
33. Staiger D, Stock JH. Instrumental Variables Regression with Weak Instruments. Econometrica 1994; 65 557–586
34. Kawano S, Uchino S, Endo A, et al. Impact of withdrawing antithrombin III administration from management of septic patients with or without disseminated intravascular coagulation. Blood Coagul Fibrinolysis 2014; 25: 795–800
35. Levi M, Toh CH, Thachil J, et al. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol 2009; 145: 24–33
36. Di Nisio M, Baudo F, Cosmi B, et al. Diagnosis and treatment of disseminated intravascular coagulation: guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb Res 2012; 129: e177–184
37. Wada H, Thachil J, Di Nisio M, et al. Guidance for diagnosis and treatment of DIC from harmonisation of the recommendations from three guidelines. J Thromb Haemost 2013; 11: 761–767
38. Wada H, Asakura H, Okamoto K, et al. Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thromb Res 2010; 125: 6–11
39. Zhang Z, Ni H, Xu X. Observational studies using propensity score analysis underestimated the effect sizes in critical care medicine. J Clin Epidemiol 2014; 67: 932–939
40. Zhang Z, Ni H, Xu X. Do the observational studies using propensity score analysis agree with randomized controlled trials in the area of sepsis? J Crit Care 2014; 29: 886 e889–815
41. Dahabreh IJ, Sheldrick RC, Paulus JK, et al. Do observational studies using propensity score methods agree with randomized trials? A systematic comparison of studies on acute coronary syndromes. Eur Heart J 2012; 33: 1893–1901
42. Vincent JL. We should abandon randomized controlled trials in the intensive care unit. Crit Care Med 2010; 38: S534–538
43. Kushimoto S, Gando S, Saitoh D, et al. Clinical course and outcome of disseminated intravascular coagulation diagnosed by Japanese Association for Acute Medicine criteria. Comparison between sepsis and trauma. Thromb Haemost 2008; 100: 1099–1105
44. Seam N, Suffredini AF. Is antithrombin treatment of disseminated intravascular coagulation a quixotic goal? Critical Care 2014; 18: 639
45. Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress syndrome: the Berlin Definition. J Am Med Assoc 2012; 307: 2526–2533
46. Tagami T, Nakamura T, Kushimoto S, et al. Early-phase changes of extravascular lung water index as a prognostic indicator in acute respiratory distress syndrome patients. Ann Intens Care 2014; 4: 27
47. Egi M, Morimatsu H, Wiedermann CJ, et al. Non-overt disseminated intravascular coagulation scoring for critically ill patients: the impact of antithrombin levels. Thromb Haemost 2009; 101: 696–705
48. Aota T, Matsumoto T, Suzuki K, et al. Antithrombin and mortality in severe pneumonia patients with sepsis-associated disseminated intravascular coagulation: an observational nationwide study: comment. J Thromb Haemost 2014; Epub ahead of print.